Secondary Primary Malignancies Rare After CAR T-Cell Immunotherapy

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 2, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, Feb. 2, 2024 -- The incidence of secondary primary malignancy after anti-CD19 chimeric antigen receptor (CAR) T-cell immunotherapy is very low, according to a study published online Jan. 24 in Nature Medicine.

Guido Ghilardi, Ph.D., from the University of Pennsylvania in Philadelphia, and colleagues describe a case of T-cell lymphoma (TCL) occurring three months after CAR T-cell immunotherapy for non-Hodgkin B-cell lymphoma, which was diagnosed from a thoracic lymph node identified at lung cancer surgery. To assess the overall risk of secondary primary malignancy after commercial CART, 449 patients treated at the University of Pennsylvania were reviewed.

The researchers found that the CAR transgene was low, while the TCL exhibited CD8+ cytotoxic phenotype and a JAK3 variant. Before CART infusion, the T-cell clone was identified at low levels in the blood, and it was detected in the lung cancer. In the cohort of patients treated at the University of Pennsylvania, 3.6 percent had secondary primary malignancy at a median follow-up of 10.3 months. For solid and hematological malignancies, the median onset time was 26.4 and 9.7 months, respectively. The projected five-year cumulative incidence was 15.2 and 2.3 percent for solid and hematological malignancies.

"The observed very low incidence of secondary T-cell lymphomas should provide reassurance to the scientific community regarding the safety of commercially available CART products," the authors write.

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-02-03 02:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords